Applied BioMath, LLC to Sponsor and Present at Antibody Engineering and Therapeutics Conference

Applied BioMath (, the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the Antibody Engineering and Therapeutics Conference December 11-15, 2017 in San Diego, CA. John Burke, PhD, will present Model Aided Drug Invention (MADI) case studies on Thursday, December 14, 2017 at 12:00 p.m. In addition to speaking at the event, Applied BioMath is also participating as a scientific briefing sponsor. 

MADI is a mathematical modeling and engineering approach to translational medicine leveraging mechanistic PKPD and Systems Pharmacology. It quantitatively integrates knowledge about therapeutics with an understanding of mechanism of action in the context of human disease mechanisms. 

Dr. Burke’s presentation will cover how quantitative modeling and simulation approaches drive critical decisions from research through clinical trials. He will demonstrate how MADI impacts biological understanding, new target proposals, lead generation, clinical candidate selection, IND support, and clinical go/no go decisions. 

“I look forward to connecting with the conference attendees to highlight how our proprietary MADI approach continues its track record of successfully helping biotechnology and pharmaceutical companies de-risk projects, accelerate development of best-in-class therapeutics, and reduce late stage attrition rates; ultimately resulting in making better therapeutics which improve patients’ lives.”
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

About Applied BioMath

Applied BioMath (, the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.    Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.   Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC. 

Press contact:
Kristen Zannella